GlassScriptPhysician profile
John D Dickinson
NPI 1780889485
$7,959.00
in general payments reported to CMS, 2019-2025
5 companies · $7,247 in 2025
The $7,247 reported for 2025 was more than what 91% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $39.61 · 2021: $114 · 2023: $233 · 2025: $7,247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,615 · Food and Beverage: $514 · Travel and Lodging: $352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,615.00 |
| Food and Beverage | $513.62 |
| Travel and Lodging | $351.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $7,359.17 | 2019-2025 | |
| Abbvie INC. | $270.55 | 2019-2021 | |
| Alcresta Therapeutics, INC. | $121.65 | 2023 | Relizorb |
| Mylan Specialty L.P. | $111.76 | 2023 | Tobi Podhaler |
| Gilead Sciences, INC. | $95.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dickinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.